Exelixis, Inc. EXEL
We take great care to ensure that the data presented and summarized in this overview for EXELIXIS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EXEL
View all-
Black Rock Inc. New York, NY33.5MShares$963 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$852 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$779 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$436 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$362 Million0.01% of portfolio
-
Lsv Asset Management Chicago, IL5.76MShares$166 Million0.28% of portfolio
-
Geode Capital Management, LLC Boston, MA5.17MShares$148 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX5.14MShares$148 Million0.03% of portfolio
-
Jpmorgan Chase & CO New York, NY5.05MShares$145 Million0.01% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL4.05MShares$116 Million0.03% of portfolio
Latest Institutional Activity in EXEL
Top Purchases
Top Sells
About EXEL
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Insider Transactions at EXEL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 28
2024
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
25,000
-4.13%
|
$700,000
$28.39 P/Share
|
Oct 03
2024
|
Michael Morrissey President and CEO |
BUY
Bona fide gift
|
Indirect |
16,298
+1.11%
|
-
|
Oct 03
2024
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Direct |
16,298
-1.66%
|
-
|
Oct 02
2024
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
96,111
-21.79%
|
$2,498,886
$26.5 P/Share
|
Oct 02
2024
|
Patrick J. Haley EVP, Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+18.48%
|
$2,400,000
$24.41 P/Share
|
Oct 01
2024
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
463,702
-32.1%
|
$12,056,252
$26.3 P/Share
|
Oct 01
2024
|
Michael Morrissey President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
480,000
+24.94%
|
$11,520,000
$24.41 P/Share
|
Sep 23
2024
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
25,000
-3.97%
|
$650,000
$26.38 P/Share
|
Aug 26
2024
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
20,000
-3.08%
|
$500,000
$25.79 P/Share
|
Aug 26
2024
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+2.98%
|
$480,000
$24.41 P/Share
|
Aug 14
2024
|
Maria C Freire Director |
SELL
Open market or private sale
|
Direct |
8,250
-8.31%
|
$214,500
$26.56 P/Share
|
Aug 13
2024
|
Julie Smith Director |
SELL
Other acquisition or disposition
|
Direct |
4,682
-30.28%
|
-
|
Aug 12
2024
|
Dana Aftab CSO/EVP Disc & Trans Research |
SELL
Open market or private sale
|
Direct |
20,883
-4.01%
|
$563,841
$27.06 P/Share
|
Aug 09
2024
|
Christopher J. Senner EVP and CFO |
SELL
Open market or private sale
|
Direct |
125,000
-14.76%
|
$3,375,000
$27.19 P/Share
|
Aug 09
2024
|
Christopher J. Senner EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+12.86%
|
$3,000,000
$24.41 P/Share
|
Aug 08
2024
|
George Poste Director |
SELL
Open market or private sale
|
Direct |
33,725
-14.49%
|
$876,850
$26.89 P/Share
|
Aug 07
2024
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
80,000
-11.26%
|
$2,000,000
$25.97 P/Share
|
Aug 07
2024
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+10.12%
|
$1,920,000
$24.41 P/Share
|
Aug 07
2024
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
14,000
-3.94%
|
$350,000
$25.5 P/Share
|
Aug 07
2024
|
Dana Aftab CSO/EVP Disc & Trans Research |
SELL
Open market or private sale
|
Direct |
95,000
-15.42%
|
$2,375,000
$25.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.33M shares |
---|---|
Bona fide gift | 133K shares |
Exercise of conversion of derivative security | 1.01M shares |
Open market or private purchase | 735K shares |
Open market or private sale | 842K shares |
---|---|
Payment of exercise price or tax liability | 878K shares |
Bona fide gift | 152K shares |
Other acquisition or disposition | 4.68K shares |